Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

1.184 +0.064 (+5.74%)
Streaming Delayed Price Updated: 9:56 AM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fate Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Forecasting The Future: 8 Analyst Projections For Fate Therapeutics ↗
 
Via Benzinga
News headline image
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Where Fate Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Evaluating Fate Therapeutics: Insights From 5 Financial Analysts ↗
 
Via Benzinga
News headline image
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cracking The Code: Understanding Analyst Reviews For Fate Therapeutics ↗
 
Via Benzinga
News headline image
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics to Present at Upcoming March Investor Conferences
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Recap: Fate Therapeutics Q4 Earnings ↗
 
Via Benzinga
News headline image
A Preview Of Fate Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Domino's To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Analyst Ratings for Fate Therapeutics ↗
 
Via Benzinga
News headline image
Recap: Fate Therapeutics Q3 Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 26, 2024 ↗
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million. 
Via Benzinga
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock ↗
Billionaire Steve Cohen is taking a massive stake in this little-known biotech company, leading FATE stock to surge more than 17%. 
Via InvestorPlace
News headline image
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pinstripes, SoFi Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 60 points on Wednesday. Shares of Pinstripes (NYSE: PNST) shares fell in pre-market trading after surging 22% on... 
Via Benzinga
Topics Stocks
News headline image
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.